@prefix dcterms: .
@prefix this: .
@prefix sub: .
@prefix prov: .
@prefix pav: .
@prefix orcid: .
@prefix codebase: .
@prefix version: .
@prefix instance: .
@prefix process: .
@prefix np: .
@prefix rdfs: .
@prefix xsd: .
@prefix has-source: .
@prefix d: .
@prefix dv: .
@prefix dr: .
@prefix npx: .
sub:head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:publicationInfo;
a np:Nanopublication .
}
sub:assertion {
d:DB00258 dv:ddi-interactor-in dr:DB00258_DB00451 .
d:DB00451 dv:ddi-interactor-in dr:DB00258_DB00451 .
dr:DB00258_DB00451 dcterms:identifier "drugbank_resource:DB00258_DB00451";
dcterms:title "DDI between Calcium Acetate and Levothyroxine - Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as levothyroxine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased."@en;
a dv:Drug-Drug-Interaction;
rdfs:label "DDI between Calcium Acetate and Levothyroxine - Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as levothyroxine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased. [drugbank_resource:DB00258_DB00451]"@en .
}
sub:provenance {
sub:assertion has-source: dr:bio2rdf.dataset.drugbank.R3 .
}
sub:publicationInfo {
sub:signature.MC0CFGVtHUCnzCoo npx:hasPublicKey "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";
npx:hasSignature "MC0CFGVtHUCnzCoofGJ8ZfAGInWhoFMpAhUAhqKn01NWkgtft09xkSkGV4J6xLk=";
npx:signedBy instance: .
this: dcterms:created "2018-03-30T11:12:45.585+02:00"^^xsd:dateTime;
dcterms:license ;
npx:hasSignatureElement sub:signature.MC0CFGVtHUCnzCoo;
prov:wasGeneratedBy process: .
instance: prov:specializationOf codebase:;
prov:wasAttributedTo orcid:0000-0002-1267-0234 .
process: dcterms:identifier "3c184e6c-ceb8-4275-a679-71dfbdac2a11";
prov:used version:;
prov:wasAssociatedWith instance:;
prov:wasStartedBy orcid:0000-0002-1267-0234 .
version: dcterms:isVersionOf codebase:;
pav:version "eda7951a5f6c622c5d2132f50c3093138484a349";
prov:wasAttributedTo orcid:0000-0002-1267-0234 .
}